Skip to content
Medical Health Aged Care

New endometriosis and chronic pelvic pain management plan to be trialled in Australia

Monash University 2 mins read

A trial of a new management plan to potentially assist thousands of Australian women who suffer from endometriosis and chronic pelvic pain is underway this month. 

Eight medical clinics located in various parts of Australia, including New South Wales, Victoria, South Australia and West Australia will be involved in trials of the new Endometriosis Management Plan (EMP). 

The EMP has been developed by Monash University’s SPHERE Centre of Research Excellence, in partnership with the Royal Australian College of General Practitioners (RACGP). The development, piloting and national release of the plan was funded  by the Australian Government Department of Health and Aged Care as part of the National Endometriosis Action Plan.

In Australia, one in seven women (14 per cent) has clinically confirmed or suspected endometriosis by age 44. 

The total economic burden of endometriosis and chronic pelvic pain per year in Australia is estimated at between $7.4 billion and $9.7 billion.

SPHERE Director and Head of the Monash University Department of General Practice, Professor Danielle Mazza AM, said endometriosis and chronic pelvic pain have critical implications for some women’s quality of life and the cause of the conditions remains uncertain.

 

“General practitioners and other clinicians can do a great deal more to support the management of endometriosis and pelvic pain within primary care settings, and to assist women to better understand and manage the condition,” Professor Mazza said.

 

“SPHERE has worked with expert clinicians, stakeholder organisations, and people with lived experience, to prepare a detailed management plan to address these sometimes debilitating and intractable medical conditions. The plan also incorporates the recommendations of the newly released National Endometriosis Guidelines.”

 

The online Endometriosis Management Plan is used to develop a tailored chronic disease management plan with patients. This involves identifying symptoms, mapping patient goals, and providing clinicians and patients with evidence-based recommendations and resources to better manage the condition. 

 

A ‘How to utilise the plan’ toolkit, with a video to assist clinicians in their practice and a resource for patients about the plan have also been developed. 

 

The Endometriosis Management Plan is focussed on supporting all general practices, and people with endometriosis and chronic pelvic pain in Australia. The EMP will be rolled out to all primary care settings in Australia in mid 2026, once the pilot and evaluation are completed.

 

Background

 

Australia was the first country to develop a roadmap and blueprint to tackle endometriosis in a nationwide coordinated manner with the National Action Plan for Endometriosis in 2018. 

 

The plan was created in partnership between the Federal Government, endometriosis experts and advocacy groups. As part of the package, the Australian Government funded the development of an Endometriosis Management Plan (EMP) in primary care settings – often the first point of contact in the healthcare system for those experiencing symptoms associated with endometriosis.

 

Through SPHERE’s investigator team, the project has links to key stakeholders and partner organisations including the Commonwealth Department of Health Endometriosis Expert Advisory Group, Primary Health Networks (PHNs), RACGP, RANZCOG, tertiary care services, and consumer groups including the Australian Coalition for Endometriosis (ACE).

 

Read more commentary on Monash Lens. 

 

For media enquiries please contact:

 

Monash University

Helena Powell – Media Advisor (medical)
E: [email protected] 

T: 0474 444 171

 

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: 03 9903 4840

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.